1. Home
  2. ARGX vs EXR Comparison

ARGX vs EXR Comparison

Compare ARGX & EXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARGX
  • EXR
  • Stock Information
  • Founded
  • ARGX 2008
  • EXR 1977
  • Country
  • ARGX Netherlands
  • EXR United States
  • Employees
  • ARGX N/A
  • EXR N/A
  • Industry
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • EXR Real Estate Investment Trusts
  • Sector
  • ARGX Health Care
  • EXR Real Estate
  • Exchange
  • ARGX Nasdaq
  • EXR Nasdaq
  • Market Cap
  • ARGX 33.0B
  • EXR 32.4B
  • IPO Year
  • ARGX 2017
  • EXR 2004
  • Fundamental
  • Price
  • ARGX $591.99
  • EXR $150.85
  • Analyst Decision
  • ARGX Strong Buy
  • EXR Buy
  • Analyst Count
  • ARGX 17
  • EXR 13
  • Target Price
  • ARGX $730.07
  • EXR $159.54
  • AVG Volume (30 Days)
  • ARGX 455.0K
  • EXR 1.1M
  • Earning Date
  • ARGX 07-31-2025
  • EXR 07-30-2025
  • Dividend Yield
  • ARGX N/A
  • EXR 4.30%
  • EPS Growth
  • ARGX N/A
  • EXR N/A
  • EPS
  • ARGX 15.94
  • EXR 4.26
  • Revenue
  • ARGX $2,643,062,000.00
  • EXR $3,363,286,000.00
  • Revenue This Year
  • ARGX $61.64
  • EXR N/A
  • Revenue Next Year
  • ARGX $32.00
  • EXR $3.24
  • P/E Ratio
  • ARGX $34.02
  • EXR $35.42
  • Revenue Growth
  • ARGX 82.13
  • EXR 15.33
  • 52 Week Low
  • ARGX $471.97
  • EXR $121.03
  • 52 Week High
  • ARGX $678.21
  • EXR $184.87
  • Technical
  • Relative Strength Index (RSI)
  • ARGX 63.19
  • EXR 55.06
  • Support Level
  • ARGX $560.91
  • EXR $147.31
  • Resistance Level
  • ARGX $575.48
  • EXR $151.74
  • Average True Range (ATR)
  • ARGX 12.76
  • EXR 2.53
  • MACD
  • ARGX 4.44
  • EXR 0.18
  • Stochastic Oscillator
  • ARGX 95.80
  • EXR 84.66

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

About EXR Extra Space Storage Inc

Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 4,000 self-storage properties in 42 states, with over 300 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.

Share on Social Networks: